Market Closed -
Nasdaq
04:00:00 2025-02-11 pm EST
5-day change
1st Jan Change
12.38 USD
-4.81%
-25.05%
-6.53%
Truist Adjusts Price Target on AnaptysBio to $30 From $20, Maintains Hold Rating
August 15, 2024 at 05:41 am EDT
Anaptys To Announce Top-Line Data From Phase 2B Trial Of Rosnilimab, A PD-1 Depleter And Agonist, In Rheumatoid Arthritis
Feb. 11
RE
AnaptysBio, Inc. Presents at Guggenheim SMID Cap Biotech Conference, Feb-05-2025 01:00 PM
Feb. 05
CORRECTION : Wolfe Initiates Coverage on AnaptysBio With Outperform Rating, $25 Price Target
Feb. 04
MT
Truist Securities Initiates Coverage on AnaptysBio With Outperform Rating, $25 Price Target
Feb. 04
MT
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab
Feb. 03
CI
Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab
Feb. 03
MT
Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab
Feb. 03
RE
AnaptysBio, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 04:30 PM
Jan. 14
Truist Securities Cuts Price Target on AnaptysBio to $20 From $30, Maintains Hold Rating
Dec. 18
MT
UBS Adjusts AnaptysBio Price Target to $18 From $33, Maintains Neutral Rating
Dec. 13
MT
Sector Update: Health Care Stocks Softer Late Afternoon
Dec. 11
MT
Sector Update: Health Care
Dec. 11
MT
Top Midday Decliners
Dec. 11
MT
HC Wainwright Downgrades AnaptysBio to Neutral From Buy, $19 Price Target
Dec. 11
MT
AnaptysBio Shares Plunge After Announcing Phase 2B Trial in Atopic Dermatitis Failed to Meet Endpoints
Dec. 11
MT
Wedbush Cuts Price Target on AnaptysBio to $40 From $42, Maintains Outperform Rating
Dec. 11
MT
AnaptysBio Says Phase 2B Trial in Atopic Dermatitis Failed to Meet Endpoints
Dec. 11
MT
Anaptys Announces Phase 2B Trial of ANB032, A Btla Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
Dec. 11
CI
AnaptysBio, Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-04-2024 01:45 PM
Dec. 04
AnaptysBio, Inc. Presents at Piper Sandler 36th Annual Healthcare Conference, Dec-03-2024 02:30 PM
Dec. 03
BTIG Downgrades AnaptysBio to Neutral From Buy
Dec. 02
MT
AnaptysBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Nov. 05
CI
UBS Adjusts Price Target on AnaptysBio to $33 From $23, Maintains Neutral Rating
24-10-30
MT
AnaptysBio Shares Fall After Eli Lilly Removes Arthritis Drug Peresolimab From Pipeline
24-10-30
MT
Truist Adjusts Price Target on AnaptysBio to $30 From $20, Maintains Hold Rating
24-08-15
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
ANAB: Dynamic Chart
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
More about the company
Last Close Price
12.38 USD
Average target price
34.73 USD
Spread / Average Target
+180.62%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1